We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Read MoreHide Full Article
Key Takeaways
IMRX began patient dosing in the phase III MAPKeeper 301 study for first-line pancreatic cancer.
MAPKeeper 301 tests atebimetinib plus mGnP versus standard-of-care GnP in metastatic PDAC.
Primary goal of the MAPKeeper study is overall survival, with top-line data expected in mid-2028.
Shares of Immuneering Corporation (IMRX - Free Report) were up 5.1% yesterday after the company announced the dosing of the first patient in a pivotal phase III study evaluating its lead product candidate, atebimetinib (IMM-1-104), in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the first-line treatment of metastatic pancreatic cancer.
The global phase III MAPKeeper 301 study will evaluate the safety and efficacy of atebimetinib, a dual MEK inhibitor plus mGnP, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received no prior systemic anti-cancer therapy.
In the MAPKeeper 301 study, patients will be randomized to receive either atebimetinib (320 mg once daily) in combination with mGnP or standard-of-care GnP alone.
The primary endpoint of the study is overall survival (OS), while key secondary endpoints include progression-free survival, overall response rate, disease control rate, safety and tolerability and quality of life.
Top-line data from the MAPKeeper 301 study is expected to be announced in mid-2028.
IMRX Price Performance
Year to date, shares of Immuneering have declined 37.4% compared with the industry’s decrease of 3.3%.
Image Source: Zacks Investment Research
IMRX's Updates on Atebimetinib Development
In January 2026, the company reported positive updated OS and safety data from the phase IIa study arm evaluating atebimetinib plus mGnP for treating first-line pancreatic cancer.
Data from the study showed that the combination of atebimetinib plus mGnP led to a 64% OS at 12 months compared to 35% for the standard of care in the given patient population.
The company is also developing atebimetinib as a monotherapy in third-line pancreatic cancer.
Beyond pancreatic cancer, Immuneering is evaluating atebimetinib in combination with Regeneron's (REGN - Free Report) anti-PD-1 therapy, Libtayo (cemiplimab), in a phase II study in patients with first-line RAS-mutant non-small-cell lung cancer (NSCLC). Dosing in the study is expected to begin in the second half of 2026.
In February 2025, Immuneering entered into a collaboration with Regeneron to evaluate atebimetinib in combination with Libtayo for treating NSCLC.
Per this agreement, Immuneering will fund the planned studies while REGN will supply Libtayo, which is approved for multiple cancer indications.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 107.7% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Key Takeaways
Shares of Immuneering Corporation (IMRX - Free Report) were up 5.1% yesterday after the company announced the dosing of the first patient in a pivotal phase III study evaluating its lead product candidate, atebimetinib (IMM-1-104), in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the first-line treatment of metastatic pancreatic cancer.
The global phase III MAPKeeper 301 study will evaluate the safety and efficacy of atebimetinib, a dual MEK inhibitor plus mGnP, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received no prior systemic anti-cancer therapy.
In the MAPKeeper 301 study, patients will be randomized to receive either atebimetinib (320 mg once daily) in combination with mGnP or standard-of-care GnP alone.
The primary endpoint of the study is overall survival (OS), while key secondary endpoints include progression-free survival, overall response rate, disease control rate, safety and tolerability and quality of life.
Top-line data from the MAPKeeper 301 study is expected to be announced in mid-2028.
IMRX Price Performance
Year to date, shares of Immuneering have declined 37.4% compared with the industry’s decrease of 3.3%.
Image Source: Zacks Investment Research
IMRX's Updates on Atebimetinib Development
In January 2026, the company reported positive updated OS and safety data from the phase IIa study arm evaluating atebimetinib plus mGnP for treating first-line pancreatic cancer.
Data from the study showed that the combination of atebimetinib plus mGnP led to a 64% OS at 12 months compared to 35% for the standard of care in the given patient population.
The company is also developing atebimetinib as a monotherapy in third-line pancreatic cancer.
Beyond pancreatic cancer, Immuneering is evaluating atebimetinib in combination with Regeneron's (REGN - Free Report) anti-PD-1 therapy, Libtayo (cemiplimab), in a phase II study in patients with first-line RAS-mutant non-small-cell lung cancer (NSCLC). Dosing in the study is expected to begin in the second half of 2026.
In February 2025, Immuneering entered into a collaboration with Regeneron to evaluate atebimetinib in combination with Libtayo for treating NSCLC.
Per this agreement, Immuneering will fund the planned studies while REGN will supply Libtayo, which is approved for multiple cancer indications.
Immuneering Corporation Price
Immuneering Corporation price | Immuneering Corporation Quote
IMRX's Zack Rank & Stocks to Consider
Immuneering currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 107.7% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.